Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.95%
0%
-29.95%
6 Months
-37.62%
0%
-37.62%
1 Year
-68.43%
0%
-68.43%
2 Years
-71.71%
0%
-71.71%
3 Years
-44.73%
0%
-44.73%
4 Years
-71.77%
0%
-71.77%
5 Years
-68.16%
0%
-68.16%
hVIVO PLC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
79.25%
EBIT Growth (5y)
32.38%
EBIT to Interest (avg)
2.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
1.51
Tax Ratio
19.80%
Dividend Payout Ratio
12.74%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
103.87%
ROE (avg)
20.51%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
1.20
EV to EBIT
1.27
EV to EBITDA
0.92
EV to Capital Employed
3.96
EV to Sales
0.19
PEG Ratio
NA
Dividend Yield
0.00%
ROCE (Latest)
311.61%
ROE (Latest)
23.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
56.00
48.50
15.46%
Operating Profit (PBDIT) excl Other Income
10.20
6.80
50.00%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
-7.10
100.00%
Consolidate Net Profit
16.10
-0.80
2,112.50%
Operating Profit Margin (Excl OI)
133.50%
80.90%
5.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 15.46% vs 31.44% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 2,112.50% vs -700.00% in Dec 2022
About hVIVO PLC 
hVIVO PLC
Miscellaneous
Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.
Company Coordinates 
Company Details
Queen Mary BioEnterprises, Innovation Centre, 42 New Road, LONDON None : E1 2AX
Registrar Details






